.png){kind=small}
.png){kind=small}
BackTable / VI / Podcast / Episode #522
Advancements in Treatment of Metastatic Ocular Melanoma
with Dr. Altan Ahmed and Dr. Sid Padia
Is there a way to treat liver metastasis secondary to uveal melanoma without introducing systemic, treatment-related toxicity? Dr. Altan Ahmed (interventional radiologist at Moffitt Cancer Center) and Dr. Sid Padia (interventional radiologist at UCLA) join guest-host Dr. Kavi Krishnasamy to discuss HEPZATO, a novel device-based treatment for liver metastases from uveal melanoma.
This podcast is supported by:
Be part of the conversation. Put your sponsored messaging on this episode. Learn how.
BackTable, LLC (Producer). (2025, March 4). Ep. 522 – Advancements in Treatment of Metastatic Ocular Melanoma [Audio podcast]. Retrieved from https://www.backtable.com
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Podcast Contributors
Synopsis
Dr. Ahmed and Dr. Padia begin by exploring the design and setup of the HEPZATO clinical trials, while also speaking on patient selection criteria. The doctors then talk through the technical aspects of the intervention. After covering workflow and considerations related to procedure timing and coordination, the doctors go on to discuss drug dosing and optimizing treatment cycles. The episode concludes with current gaps in literature, current and future research aims, and potential future applications of the HEPZATO modality in treating other malignancies such as colorectal cancer.
Timestamps
00:00 - Introduction
05:40 - Patient Selection Criteria
09:49 - Workflow
19:17 - Procedure Timing and Coordination
29:39 - Challenges and Considerations in Drug Dosing
32:39 - Optimizing Treatment Cycles and Patient Response
37:56 - Managing Post-Treatment and Adverse Effects
43:43 - Future Research and Gaps in Current Interventions
50:45 - Exploring New Applications for PHP Therapy
55:02 - Conclusion
Resources
Hepzato:
https://hepzatokit.com/
FOCUS Trial - Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study:
https://pubmed.ncbi.nlm.nih.gov/38704501/
FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A):
https://ascopubs.org/doi/pdf/10.1200/JCO.2022.40.16_suppl.9510
Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial:
https://pubmed.ncbi.nlm.nih.gov/36624292/
Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11010739/
Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7801354/
Southampton group - Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10906212/
Leiden group - Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases:
https://pubmed.ncbi.nlm.nih.gov/38587534/
Transcript Preview
Are you treating patients with hepatocellular carcinoma and wondering how to better integrate surgery, local regional therapies, and systemic treatment options? Check out the latest CME course on Backtable Plus, multidisciplinary approach and combination therapies for HTC.
You'll hear from experts across interventional radiology, hepatology, oncology, and surgery as they break down current data, referral coordination, and practical workflows for real-world HTC care. It's concise, actionable, and available now at plus.backtable.com. Log in, level up your tumor reward game, and earn CME along the way. That's a multidisciplinary approach and combination therapies for HTC, only on BackTable+.
The Materials available on BackTable are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Up Next
Articles
Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma: Techniques & Treatment Gaps
HEPZATO for Uveal Melanoma Metastasis: Patient Selection, Dosing & Treatment Cycles
Topics
